BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Goto H, Hidaka D, Yamamoto S, et al. (2020) Feasibility and efficacy of low-dose pegfilgrastim for CD34 cell mobilization in lymphoma. Journal of Clinical Apheresis. 35: 413-419 |
Hashimoto D. (2020) [Graft-versus-host disease: new insights into disease pathogenesis]. [Rinsho Ketsueki] the Japanese Journal of Clinical Hematology. 61: 959-964 |
Ara T, Hashimoto D, Hayase E, et al. (2020) Intestinal goblet cells protect against GVHD after allogeneic stem cell transplantation via Lypd8. Science Translational Medicine. 12 |
Hashimoto D. (2020) [Animal models in the study of allogeneic hematopoietic stem cell transplantation]. [Rinsho Ketsueki] the Japanese Journal of Clinical Hematology. 61: 369-378 |
Peled JU, Gomes ALC, Devlin SM, et al. (2020) Microbiota as Predictor of Mortality in Allogeneic Hematopoietic-Cell Transplantation. The New England Journal of Medicine. 382: 822-834 |
Stein-Thoeringer CK, Nichols KB, Lazrak A, et al. (2019) Lactose drives expansion to promote graft-versus-host disease. Science (New York, N.Y.). 366: 1143-1149 |
Yokoyama E, Hashimoto D, Hayase E, et al. (2019) Short-term KRP203 and posttransplant cyclophosphamide for graft-versus-host disease prophylaxis. Bone Marrow Transplantation |
Yamahara K, Hamada A, Soma T, et al. (2019) Safety and efficacy of amnion-derived mesenchymal stem cells (AM01) in patients with steroid-refractory acute graft-versus-host disease after allogeneic haematopoietic stem cell transplantation: a study protocol for a phase I/II Japanese trial. Bmj Open. 9: e026403 |
Matsuoka S, Hashimoto D, Kadowaki M, et al. (2019) The myeloid differentiation factor 88 signaling in donor T cells accelerates graft-versus-host disease. Haematologica |
Hidaka D, Onozawa M, Miyashita N, et al. (2019) Imetelstat Sensitizes Hematopoietic Malignancy Cells to Genotoxic Agent Via Suppression of Telomerase Mediated DNA Repair Process Blood. 134: 3369-3369 |